2-<(3-Chlororophenyl)oxymethyl>benzoic acid | 60086-49-9

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: 2-<(3-Chlororophenyl)oxymethyl>benzoic acid
• 英文别名: [(3-chlorophenoxy)methyl]benzoic acid；2-(3-chlorophenoxymethyl) benzoic acid；2-(3-chlorophenoxymethyl)-benzoic acid；2-(3-Chlorphenoxymethyl)-benzoesaeure；2-[(3-chlorophenoxy)methyl]benzoic acid
• CAS: 60086-49-9
• 化学式: C₁₄H₁₁ClO₃
• mdl: MFCD12072101
• 分子量: 262.693
• InChiKey: LGHCZVSOBXVGPI-UHFFFAOYSA-N

物化性质

• 沸点：
  422.5±25.0 °C(Predicted)
• 密度：
  1.322±0.06 g/cm3(Temp: 20 °C; Press: 760 Torr)(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  3.5
• 重原子数：
  18
• 可旋转键数：
  4
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.071
• 拓扑面积：
  46.5
• 氢给体数：
  1
• 氢受体数：
  3

反应信息

• 作为反应物：
  描述：

  2-<(3-Chlororophenyl)oxymethyl>benzoic acid 在 aluminum (III) chloride 、 草酰氯 、 palladium diacetate 、 caesium carbonate 、 N,N-二甲基甲酰胺 、 2-二环己基磷-2,4,6-三异丙基联苯 作用下， 以 1,4-二氧六环 、 二氯甲烷 、 叔丁醇 为溶剂， 反应 4.0h， 生成 N-[4-methyl-3-[(11-oxo-6H-benzo[c][1]benzoxepin-3-yl)amino]phenyl]benzamide
  参考文献：
  名称：

  Targeting the Hinge Glycine Flip and the Activation Loop: Novel Approach to Potent p38α Inhibitors

  摘要：

  The p38 MAP kinase is a key player in signaling pathways regulating the biosynthesis of inflammatory cytokines. Small molecule p38 inhibitors suppress the production of these cytokines. Therefore p38 is a promising drug target for novel anti-inflammatory drugs. In this study, we report novel dibenzepinones, dibenzoxepines, and benzosuberones as p38 alpha MAP kinase inhibitors. Previously reported dibenzepinones and dibenzoxepines were chemically modified by introduction of functional groups or removal of a phenyl ring. This should result in targeting of the hydrophobic region I, the "deep pocket", and the hinge glycine flip of the kinase. Potent inhibitors with IC50 values in the single digit nanomolar range (up to 3 nM) were identified. Instead of targeting the "deep pocket" in the DFG-out conformation, interactions with the DFG-motif in the in-conformation could be observed by protein X-ray crystallography.

  DOI：

  10.1021/jm300951u
• 作为产物：
  描述：

  2-(溴甲基)苯甲酸乙酯 在 水 、 sodium ethanolate 、 sodium hydroxide 作用下， 以 乙醇 为溶剂， 反应 7.5h， 生成 2-<(3-Chlororophenyl)oxymethyl>benzoic acid
  参考文献：
  名称：

  二苯并[b，f] [1,4]氮杂ze庚因和二苯并[b，e] Oxepinesine：在H1R，H4R，5-HT2AR和其他选定的GPCR中，氯取代方式对药理学的影响。

  摘要：

  受到VUF6884（7-Chloro-11-（4-methylpiperazin-1-yl）dibenzo [b，f] [1,4] oxazep​​ine的启发），报道为双重H1 / H4受体配体（pKi：8.11（人H1R（ hH1R）），7.55（人H4R（hH4R））），四种已知的和28种新的奥氮平及其相关的奥西平衍生物已合成，并在组胺受体和选定的胺能GPCR上进行了药理学表征。与奥氮平系列相反，在奥西平系列中，新化合物显示出对hH1R的高亲和力（pKi：6.8-8.7），但对hH4R的亲和力不高（pKi：≤5.3）。对于一种oxepine衍生物（1-（2-氯-6,11-二氢二苯并[b，e] oxepin-11-基] -4-甲基哌嗪），对映体被分离，R-对映体被鉴定为是对映体。 hH1R（pKi：8.83（R），7.63（S））和豚鼠H1R（gpH1R）（pKi：8.82（R），7.

  DOI：

  10.1016/j.phrs.2016.09.042

文献信息

• Synthesis and Biological Activity of 11-(4-(Cinnamyl)-1-piperazinyl)-6,11-dihydrodibenz(b,e)oxepin Derivatives, Potential Agents for the Treatment of Cerebrovascular Disorders.
  作者：Mikio KUROKAWA、Fuminori SATO、Yoshinobu MASUDA、Takayuki YOSHIDA、Yuko OCHI、Kayoko ZUSHI、Iwao FUJIWARA、Shunsuke NARUTO、Hitoshi UNO、Jun-ichi MATSUMOTO

  DOI：10.1248/cpb.39.2564

  日期：——

  A series of 11-[4-(cinnamyl)-1-piperazinyl]-6, 11-dihydrodibenz[b, e]oxepins and related compounds were synthesized and evaluated for their protective activities against complete ischemia, normobaric hypoxia, lipidperoxidation and convulsion. Structure-activity relationship studies of this series led to the finding of (E)-1-(3-fluoro-6, 11-dihydrodibenz[b, e]oxepin-11-yl)-4-(3-phenyl-2-propenyl)piperazine dimaleate (50), AJ-3941 with the most appropriate property for combined pharmacological activities.

  合成了一系列11-[4-（肉桂基）-1-哌嗪基]-6，11-二氢二苯并[b，e]氧芴及其相关化合物，并评价了它们对完全缺血、常压缺氧、脂质过氧化和惊厥的保护活性。通过对这一系列化合物的构效关系研究，发现了（E）-1-（3-氟-6，11-二氢二苯并[b，e]氧芑-11-基）-4-（3-苯基-2-丙烯基）哌嗪二马来酸盐（50），AJ-3941，它具有最适合的联合药理活性。
• Pharmaceutical compositions and method of producing anti-psychotic
  申请人：SmithKline Corporation

  公开号：US04086350A1

  公开（公告）日：1978-04-25

  Tricyclic piperidylidene derivatives administered internally to an animal host, in therapeutically effective amounts, produce antipsychotic activity without extrapyramidal symptoms. Certain of the active ingredients are novel compounds per se.

  三环哌啶基衍生物在动物宿主内部以治疗有效剂量给药，能产生抗精神病活性，而不会出现锥体外症状。其中一些活性成分是新颖的化合物本身。
• 4-Aminoquinolines:  Novel Nociceptin Antagonists with Analgesic Activity
  作者：Hisashi Shinkai、Takao Ito、Tetsuya Iida、Yuki Kitao、Hideki Yamada、Itsuo Uchida

  DOI：10.1021/jm0002073

  日期：2000.11.1

  Small-molecule nociceptin antagonists were synthesized to examine their therapeutic potential. After a 4-aminoquinoline derivative was found to bind with the human ORL1 receptor, a series of 4-aminoquinolines and related compounds were synthesized and their binding was evaluated. Elucidation of structure-activity relationships eventually led to the optimum compounds. One of the se compounds, N-(4-amino-2-methylquinolin-6-yl) -2-(4-ethylphenoxymethyl)benzamide hydrochloride (11) not only antagonized nociceptin-induced allodynia in mice but also showed analgesic effect in a hot plate test using mice and in a formalin test using rats. Its analgesic effect was not antagonized by the opioid antagonist naloxone. These results indicate that this nociceptin antagonist has the potential to become a novel type of analgesic that differs from mu -opioid agonists.
• US4086350A
  申请人：——

  公开号：US4086350A

  公开（公告）日：1978-04-25